Calcitriol - Berg Pharma

Drug Profile

Calcitriol - Berg Pharma

Alternative Names: 31543; API-31543; BPM-31543

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berg Pharma
  • Developer Cure Pharmaceutical
  • Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alopecia
  • Preclinical Myelosuppression

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase I trial in Chemotherapy-induced alopecia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Mar 2017 Berg completes a phase I trial in chemotherapy-induced Alopecia in USA (Topical) (NCT01588522)
  • 06 Dec 2016 Interim efficacy, adverse events and pharmacokinetics data from a phase I trial in Chemotherapy-induced alopecia presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top